GLP-2 Agonist Treatment for Short Bowel Syndrome Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with short bowel syndrome (SBS) experience malabsorption and require expensive and life-threatening long-term parenteral nutrition due to insufficient intestinal absorption, which is exacerbated by low GLP-2 levels following intestinal resection, especially in those without colon-in-continuity.
Innovation Solution
Treatment with a GLP-2 receptor agonist, such as teduglutide, administered to SBS patients with at least 25% colon-in-continuity to enhance intestinal absorption by stimulating GLP-2 receptors and promoting intestinal growth and adaptation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term parenteral nutrition is used to treat SBS patients, then life is saved and nutritional needs are met, but quality of life is impaired and serious complications occur
Solution Approach 1:
The patent uses GLP-2 receptor agonists as intermediary substances that mediate between the intestinal failure condition and the nutritional support need. These agonists stimulate endogenous GLP-2 receptors to promote intestinal adaptation and absorption, serving as a bridge that reduces dependence on parenteral nutrition while avoiding its complications
Solution Approach 2:
The treatment enables the intestinal system to serve itself by stimulating endogenous repair mechanisms through GLP-2 receptor agonists. The body's own intestinal cells respond to the agonists by increasing absorption capacity and adapting to the reduced intestinal mass, reducing the need for external parental support
2Object-affected harmful factors
If intestinal resection is performed to treat underlying conditions, then the primary disease is managed, but intestinal absorption capacity is reduced leading to SBS
Solution Approach 1:
The patent applies GLP-2 receptor agonists in advance to maximize intestinal adaptation before the full impact of resection is realized. By administering the agonists early in the post-resection period, the treatment promotes crypt cell proliferation and villus growth during the critical adaptation window, preserving absorption capacity before malabsorption sets in
Solution Approach 2:
The treatment changes the physiological parameters of the intestinal tissue by stimulating GLP-2 receptors, which alters cell proliferation rates, apoptosis inhibition, and tissue growth patterns. These parameter changes enable the remaining intestine to compensate for the resected portion through hypertrophy and hyperplasia
3Ease of manufacture
If SBS patients have no colon-in-continuity, then surgical resection is more complete, but GLP-2 levels are low and adaptive response is minimal
Solution Approach 1:
The GLP-2 receptor agonist serves as an intermediary that compensates for the absence of endogenous GLP-2 production in patients without colon-in-continuity. By providing exogenous agonists that bind to remaining GLP-2 receptors in the small intestine, the treatment bypasses the need for colonic L-cells to produce GLP-2, enabling adaptive response despite complete colonic resection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases absolute wet weight absorption, reduces fecal wet weight, and improves energy absorption in SBS patients with colon-in-continuity, potentially reducing the need for parenteral nutrition and improving quality of life.
Implementation Method 1
GLP-2 functions to slow gastric emptying, reduce gastric secretions, increase intestinal blood-flow and stimulate growth of the small and large intestine. In animal studies, GLP-2 administration induces mucosal epithelial proliferation in the stomach and small and large intestine by stimulation of crypt cell proliferation and inhibition of enterocyte apoptosis.
Data Source
AI summary
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.